Researchers from the Massachusetts Institute of Technology have developed a set of enzyme-targeting nanoscale tools to monitor cancer progression and treatment response in real time, map enzyme activity to precise locations within a tumor, and isolate relevant cell populations for analysis. The tests rely on nanoparticles that interact with tumor proteins. The nanoparticles are coated with peptides (short protein fragments) that target these proteins. When the nanoparticles arrive at a tumor site, the peptides are cut and release biomarkers that can be detected in the urine.
An official website of the United States government.